Last updated: 19 June 2019 at 2:30am EST

Robert Coffman Net Worth




The estimated Net Worth of Robert Coffman is at least 1.81 百万$ dollars as of 28 February 2019. Robert Coffman owns over 63,202 units of Dynavax Technologies stock worth over 848,449$ and over the last 20 years Robert sold DVAX stock worth over 961,124$.

Robert Coffman DVAX stock SEC Form 4 insiders trading

Robert has made over 15 trades of the Dynavax Technologies stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert sold 63,202 units of DVAX stock worth 570,714$ on 28 February 2019.

The largest trade Robert's ever made was selling 63,202 units of Dynavax Technologies stock on 28 February 2019 worth over 570,714$. On average, Robert trades about 6,162 units every 127 days since 2004. As of 28 February 2019 Robert still owns at least 77,768 units of Dynavax Technologies stock.

You can see the complete history of Robert Coffman stock trades at the bottom of the page.



What's Robert Coffman's mailing address?

Robert's mailing address filed with the SEC is C/O DYNAVAX TECHNOLOGY CORPORATION, 2929 SEVENTH STREET, SUITE 130, BERKELEY, CA, 94710.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over 196,839,440$ worth of Dynavax Technologies stock and bought 2,463,112 units worth 11,318,051$ . The most active insiders traders include Andrew A. F. HackPartners L P/Ilbiotechnolog...James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of 1,533,390$. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth 43,127$.



What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.



What does Dynavax Technologies's logo look like?

Dynavax Technologies Corp. logo

Complete history of Robert Coffman stock trades at Dynavax Technologies

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
28 Feb 2019 Robert Coffman
副総裁、Chief Scientific Officer
販売 63,202 9.03$ 570,714$
28 Feb 2019
77,768
13 Dec 2017 Robert Coffman
副総裁、Chief Scientific Officer
オプション行使 7,500 5.40$ 40,500$
13 Dec 2017
13,808
18 Dec 2012 Robert Coffman
副総裁、Chief Scientific Officer
オプション行使 19,926 1.50$ 29,889$
18 Dec 2012
57,918
6 Nov 2012 Robert Coffman
副総裁、Chief Scientific Officer
オプション行使 8,000 1.50$ 12,000$
6 Nov 2012
27,926
5 Oct 2012 Robert Coffman
副総裁、Chief Scientific Officer
販売 8,000 4.94$ 39,520$
5 Oct 2012
37,992
13 Sep 2012 Robert Coffman
副総裁、Chief Scientific Officer
販売 8,000 4.52$ 36,160$
13 Sep 2012
3,111
5 Sep 2012 Robert Coffman
副総裁、Chief Scientific Officer
オプション行使 16,000 4.09$ 65,440$
5 Sep 2012
25,325
20 Jun 2012 Robert Coffman
副総裁、Chief Scientific Officer
オプション行使 8,000 4.13$ 33,040$
20 Jun 2012
41,325
11 Nov 2011 Robert Coffman
副総裁、Chief Scientific Officer
オプション行使 60,000 28.40$ 1,704,000$
11 Nov 2011
89,333
1 Sep 2005 Robert Coffman
副総裁、Chief Scientific Officer
販売 6,000 6.41$ 38,460$
1 Sep 2005
40,444
1 Jun 2005 Robert Coffman
副総裁、Chief Scientific Officer
販売 6,000 3.68$ 22,080$
1 Jun 2005
46,444
1 Mar 2005 Robert Coffman
副総裁、Chief Scientific Officer
販売 6,000 5.27$ 31,620$
1 Mar 2005
52,444
3 Dec 2004 Robert Coffman
副総裁、Chief Scientific Officer
販売 4,500 6.44$ 28,980$
3 Dec 2004
58,444
1 Dec 2004 Robert Coffman
副総裁、Chief Scientific Officer
販売 1,500 7.06$ 10,590$
1 Dec 2004
62,943
24 Nov 2004 Robert Coffman
副総裁、Chief Scientific Officer
販売 30,000 6.10$ 183,000$
24 Nov 2004
64,443


Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include: